Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U8VY
|
|||
| Former ID |
DIB018914
|
|||
| Drug Name |
quinazoline deriv. 1
|
|||
| Synonyms |
Aurora Kinase Inhibitor II; quinazoline deriv 1; 331770-21-9; CHEMBL382590; -Benzamidoanilino)-6,7-dimethoxyquinazoline; N-{4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl}benzamide; N-[4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenyl]benzamide; Anilinoquinazoline1; K00590a; CBiol_002061; 4-(4'-Benzamidoanilino)-6,7-dimethoxyquinazoline; GTPL5930; SCHEMBL1066538; AC1O7M16; CTK8E8821; BDBM12403; DTXSID00425012; MolPort-044-561-446; Bio1_000347; ZINC590935; HMS3229A17; Bio1_001325; Bio1_000836; IN1528; CCG-206735
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H20N4O3
|
|||
| Canonical SMILES |
COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)NC(=O)C4=CC=CC=C4)OC
|
|||
| InChI |
1S/C23H20N4O3/c1-29-20-12-18-19(13-21(20)30-2)24-14-25-22(18)26-16-8-10-17(11-9-16)27-23(28)15-6-4-3-5-7-15/h3-14H,1-2H3,(H,27,28)(H,24,25,26)
|
|||
| InChIKey |
IMYVCWQAHSYYOO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 331770-21-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora B messenger RNA (AURKB mRNA) | Target Info | Inhibitor | [2] |
| Aurora kinase C (AURKC) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Oocyte meiosis | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling by Aurora kinases | ||||
| Aurora C signaling | ||||
| FOXM1 transcription factor network | ||||
| Aurora A signaling | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Separation of Sister Chromatids | ||||
| Resolution of Sister Chromatid Cohesion | ||||
| RHO GTPases Activate Formins | ||||
| Mitotic Prometaphase | ||||
| WikiPathways | Mitotic Metaphase and Anaphase | |||
| Mitotic Prometaphase | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | ||||
| Gastric Cancer Network 1 | ||||
| Integrated Breast Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5930). | |||
| REF 2 | A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.